Register
Adjunct dapagliflozin treatment improves glycemic control in patients with type 1 diabetes |
Journal Updates
eMediNexus Coverage from: 
Adjunct dapagliflozin treatment improves glycemic control in patients with type 1 diabetes

0 Read Comments                

Addition of dapagliflozin to intensive insulin therapy in adults with type 1 diabetes who had suboptimal glycemic control reduced blood glucose, aided in weight loss and led to a reduction in insulin doses. However, it also slightly increased the risk of diabetic ketoacidosis risk. These findings from the DEPICT-2 Study were presented June 24, 2018 at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now